Ramesh Jayaraman

Employment

• TheraIndx Lifesciences Pvt ltd Chief Scientific Officer

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (9)

• Neutropenic Rat Thigh Infection Model for Evaluation of the Pharmacokinetics/Pharmacodynamics of Anti-Infectives
  Microbiology Spectrum 2023 DOI: 10.1128/spectrum.00133-23
  +Save
• Pharmacokinetics/Pharmacodynamics (PK/PD) of Ciprofloxacin in the Complicated Urinary Tract Infection (cUTI) Model in Diabetic Mice
  Current Drug Metabolism 2020 DOI: 10.2174/1389200221666200310105227
  +Save
• Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans.
  Drug metabolism letters 2015 DOI: 10.2174/1872312809666150119105250
  +Save
• Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 DOI: 10.1200/jco.2012.42.5223
  +Save
• The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.
  Blood cancer journal 2012 DOI: 10.1038/bcj.2012.14
  +Save
• Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JA…
  Journal of medicinal chemistry 2012 DOI: 10.1021/jm201454n
  +Save
• Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus …
  Journal of medicinal chemistry 2011 DOI: 10.1021/jm201112g
  +Save
• SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.
  Leukemia 2011 DOI: 10.1038/leu.2011.148
  +Save
• Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor…
  Journal of medicinal chemistry 2011 DOI: 10.1021/jm200326p
  +Save